Payment overview · 2025
General Payments
$449.20
27 reported records · 8 companies
Healthcare provider profile · identity verified
Harry Anthony Alexander, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · THOMASVILLE, NC · NPI 1316916653
Verified facts
What the public records show
CMS Open Payments records show Harry Anthony Alexander, M.D. received $449.20 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.10 | 40.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.41 | 17.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.52 | 16.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.24 | 8.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.94 | 7.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.27 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.27 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.45 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $449.20 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.43 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.47 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
106 | 83 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 610 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 160 |
| Losartan Potassium | Losartan Potassium | 440 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 437 | 121 |
| Alprazolam | Alprazolam | 369 | 59 |
| Lisinopril | Lisinopril | 346 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 85 |
| Furosemide | Furosemide | 281 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 77 |
| Prednisone | Prednisone | 265 | 167 |
| Omeprazole | Omeprazole | 260 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 258 | 75 |
| Metformin Hcl | Metformin Hcl | 243 | 66 |
| Atenolol | Atenolol | 233 | 61 |
| Gabapentin | Gabapentin | 207 | 72 |
| Meloxicam | Meloxicam | 196 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 56 |
| Potassium Chloride | Potassium Chloride | 155 | 48 |
| Lorazepam | Lorazepam | 136 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 37 |
| Glipizide Er | Glipizide | 125 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 46 |
| Doxazosin Mesylate | Doxazosin Mesylate | 120 | 35 |
| Trazodone Hcl | Trazodone Hcl | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 112 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 31 |
| Glipizide | Glipizide | 111 | 31 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 110 | 110 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 106 | 83 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 78 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 26 |
| Ozempic | Semaglutide | 93 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 24 |
| Eliquis | Apixaban | 81 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | suppressed |
| Allopurinol | Allopurinol | 79 | 23 |
| Carvedilol | Carvedilol | 74 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 72 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | suppressed |
| Famotidine | Famotidine | 71 | 21 |
| Bupropion Xl | Bupropion Hcl | 69 | 22 |
| Baclofen | Baclofen | 68 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Montelukast Sodium | Montelukast Sodium | 65 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 16 |
| Azithromycin | Azithromycin | 55 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 16 |
| Spironolactone | Spironolactone | 50 | 14 |
| Levofloxacin | Levofloxacin | 48 | 35 |
| Estradiol | Estradiol | 47 | 14 |
| Finasteride | Finasteride | 46 | 14 |
| Alendronate Sodium | Alendronate Sodium | 45 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Trulicity | Dulaglutide | 43 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 21 |
| Amiloride Hcl | Amiloride Hcl | 39 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 35 | 11 |
| Amoxicillin | Amoxicillin | 34 | 31 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 31 | 31 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 14 |
| Cephalexin | Cephalexin | 29 | 24 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Torsemide | Torsemide | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Fluocinonide | Fluocinonide | 21 | 12 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 16 |
| Jardiance | Empagliflozin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $449.20 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error